Arcoma AB (ARCOMA.ST)
SEK 10.95
(3.3%)
SEK 10.95
(3.3%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 163.01 Million SEK | 30.36% |
| 2022 | 125.04 Million SEK | 6.76% |
| 2021 | 117.13 Million SEK | -0.24% |
| 2020 | 117.41 Million SEK | -12.16% |
| 2019 | 133.67 Million SEK | 11.89% |
| 2018 | 119.47 Million SEK | 30.07% |
| 2017 | 91.84 Million SEK | -10.02% |
| 2016 | 102.08 Million SEK | -17.2% |
| 2015 | 123.28 Million SEK | -5.48% |
| 2014 | 130.43 Million SEK | 28.74% |
| 2013 | 101.31 Million SEK | -31.39% |
| 2012 | 147.66 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 41.65 Million SEK | -10.35% |
| 2024 Q3 | 31.88 Million SEK | -23.45% |
| 2024 Q1 | 46.46 Million SEK | -9.47% |
| 2023 Q3 | 35.85 Million SEK | -6.24% |
| 2023 Q1 | 37.58 Million SEK | -8.89% |
| 2023 FY | 163.01 Million SEK | 30.36% |
| 2023 Q4 | 51.32 Million SEK | 43.14% |
| 2023 Q2 | 38.24 Million SEK | 1.75% |
| 2022 Q1 | 24.29 Million SEK | 14.51% |
| 2022 FY | 125.04 Million SEK | 6.76% |
| 2022 Q4 | 41.25 Million SEK | 42.22% |
| 2022 Q2 | 30.83 Million SEK | 26.94% |
| 2022 Q3 | 29 Million SEK | -5.93% |
| 2021 Q1 | 36.88 Million SEK | 21.94% |
| 2021 Q4 | 21.21 Million SEK | -8.43% |
| 2021 Q2 | 35.88 Million SEK | -2.7% |
| 2021 Q3 | 23.16 Million SEK | -35.45% |
| 2021 FY | 117.13 Million SEK | -0.24% |
| 2020 Q2 | 31.54 Million SEK | -5.53% |
| 2020 Q1 | 33.39 Million SEK | -4.13% |
| 2020 Q3 | 22.23 Million SEK | -29.52% |
| 2020 Q4 | 30.24 Million SEK | 36.05% |
| 2020 FY | 117.41 Million SEK | -12.16% |
| 2019 Q2 | 33.87 Million SEK | -2.16% |
| 2019 Q4 | 34.83 Million SEK | 14.82% |
| 2019 Q3 | 30.33 Million SEK | -10.46% |
| 2019 Q1 | 34.62 Million SEK | 1.73% |
| 2019 FY | 133.67 Million SEK | 11.89% |
| 2018 Q4 | 34.03 Million SEK | 16.21% |
| 2018 FY | 119.47 Million SEK | 30.07% |
| 2018 Q3 | 29.29 Million SEK | -5.17% |
| 2018 Q2 | 30.88 Million SEK | 22.25% |
| 2018 Q1 | 25.26 Million SEK | 0.65% |
| 2017 Q1 | 22.99 Million SEK | -27.31% |
| 2017 FY | 91.84 Million SEK | -10.02% |
| 2017 Q4 | 25.1 Million SEK | 48.18% |
| 2017 Q3 | 16.94 Million SEK | -36.8% |
| 2017 Q2 | 26.8 Million SEK | 16.56% |
| 2016 FY | 102.08 Million SEK | -17.2% |
| 2016 Q4 | 31.63 Million SEK | 21.2% |
| 2016 Q3 | 26.1 Million SEK | 2.12% |
| 2016 Q2 | 25.56 Million SEK | 36.64% |
| 2016 Q1 | 18.7 Million SEK | -46.78% |
| 2015 Q1 | 37.57 Million SEK | 31.7% |
| 2015 Q2 | 25.2 Million SEK | -32.93% |
| 2015 Q3 | 25.35 Million SEK | 0.61% |
| 2015 FY | 123.28 Million SEK | -5.48% |
| 2015 Q4 | 35.15 Million SEK | 38.62% |
| 2014 Q1 | 34.66 Million SEK | 34.23% |
| 2014 Q2 | 39.19 Million SEK | 13.09% |
| 2014 Q3 | 27.61 Million SEK | -29.54% |
| 2014 Q4 | 28.53 Million SEK | 3.31% |
| 2014 FY | 130.43 Million SEK | 28.74% |
| 2013 Q3 | 22.22 Million SEK | 0.0% |
| 2013 FY | 101.31 Million SEK | -31.39% |
| 2013 Q4 | 25.82 Million SEK | 16.17% |
| 2012 FY | 147.66 Million SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Acarix AB (publ) | 6.24 Million SEK | -2512.001% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 88.127% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 88.127% |
| Bactiguard Holding AB (publ) | 203.99 Million SEK | 20.087% |
| BICO Group AB (publ) | 2.23 Billion SEK | 92.721% |
| Boule Diagnostics AB (publ) | 571.32 Million SEK | 71.467% |
| CellaVision AB (publ) | 677.29 Million SEK | 75.931% |
| Clinical Laserthermia Systems AB (publ) | 8.27 Million SEK | -1870.446% |
| Chordate Medical Holding AB (publ) | 976.28 Thousand SEK | -16597.549% |
| C-Rad AB (publ) | 424.61 Million SEK | 61.609% |
| Duearity AB (publ) | 1.65 Million SEK | -9755.804% |
| Dignitana AB (publ) | 86.06 Million SEK | -89.414% |
| Episurf Medical AB (publ) | 10.3 Million SEK | -1482.67% |
| Getinge AB (publ) | 31.82 Billion SEK | 99.488% |
| Scandinavian Real Heart AB (Publ) | - SEK | -Infinity% |
| Iconovo AB (publ) | 7.07 Million SEK | -2203.029% |
| Integrum AB (publ) | 104.11 Million SEK | -56.567% |
| Luxbright AB (publ) | 854.69 Thousand SEK | -18972.796% |
| Mentice AB (publ) | 273.61 Million SEK | 40.421% |
| OssDsign AB (publ) | 112.15 Million SEK | -45.345% |
| Paxman AB (publ) | 210.11 Million SEK | 22.417% |
| Promimic AB (publ) | 37.07 Million SEK | -339.749% |
| Qlife Holding AB (publ) | 244 Thousand SEK | -66709.426% |
| SciBase Holding AB (publ) | 23.24 Million SEK | -601.291% |
| ScandiDos AB (publ) | 60.42 Million SEK | -169.763% |
| Sectra AB (publ) | 2.96 Billion SEK | 94.499% |
| Sedana Medical AB (publ) | 153.86 Million SEK | -5.945% |
| Senzime AB (publ) | 35.75 Million SEK | -355.935% |
| SpectraCure AB (publ) | 318 Thousand SEK | -51162.579% |
| Stille AB | 294.89 Million SEK | 44.721% |
| Vitrolife AB (publ) | 3.51 Billion SEK | 95.358% |
| Xvivo Perfusion AB (publ) | 597.54 Million SEK | 72.719% |